AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (previously presented) A compound of formula:



(I)

or a pharmaceutically acceptable salt thereof, wherein

A is $-NR^4-$, -O-, or -S-;

R^1 is -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R^2 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_8-C_{14})$tricycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_8-C_{14})$bicycloalkenyl, $-(C_8-C_{14})$tricycloalkenyl, $-(C_3-C_7)$heterocycle, or $-(C_7-C_{10})$bicycloheterocycle, each of which is unsubstituted or substituted with one or more R^5 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$aryl, or $-(C_5-C_{10})$heteroaryl, each of which is unsubstituted or substituted with one or more R^7 groups;

each R^3 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$; or

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(C_3-C_7)heterocycle, or -(C_7-C_{10})bicycloheterocycle, each of which is unsubstituted or substituted with one or more R^5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(C_5-C_{10})heteroaryl, each of which is unsubstituted or substituted with one or more R^7 groups;

R^4 is -(C_1-C_6)alkyl, or -O-(C_1-C_6)alkyl;

each R^5 is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -halo, -N_3, -NO_2, -$N(R^8)_2$, -CH=NR^8, -NR^8OH, -OR^8, -COR^8, -C(O)OR^8, -OC(O)R^8, -OC(O)OR^8, -SR^8, -S(O)R^8, or -$S(O)_2R^8$;

R^6 is -phenyl, -naphthyl, -(C_3-C_8)cycloalkyl, -(C_{14})aryl, or -(C_5-C_{10})heteroaryl, each of which is unsubstituted or substituted with one or more R^7 groups;

each R^7 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(C_3-C_5)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -$N(R^8)_2$, -CH=NR^8, -NR^8OH, -OR^8, -COR^8, -C(O)OR^8, -OC(O)R^8, -OC(O)OR^8, -SR^8, -S(O)R^8, or -$S(O)_2R^8$;

each R^8 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(C_3-C_5)heterocycle, -C(halo)$_3$, -CH_2(halo), or -CH(halo)$_2$;

each halo is independently -F, -Cl, -Br or -I;

n is an integer ranging from 0 to 3; and

m is an integer ranging from 0 to 2.

2. (original) The compound of claim 1, wherein A is -NR^4-.

3. (original) The compound of claim 2, wherein:

n is 0;

m is 0; and

R^6 is phenyl.

4. (original) The compound of claim 3, wherein the R^6 phenyl is unsubstituted.

5. (original) The compound of claim 3, wherein the R^6 phenyl is substituted at the 4-position.

6. (original) The compound of claim 5, wherein the R^6 phenyl is substituted with a -(C_1-C_6)alkyl.

7. (original) The compound of claim 6, wherein the -(C_1-C_6)alkyl is a *tert*-butyl group.

8. (original) The compound of claim 6, wherein the -(C_1-C_6)alkyl is an *iso*-propyl group.

9. (original) The compound of claim 5, wherein the R^6 phenyl is substituted with a -CF_3 group.

10. (original) The compound of claim 3, wherein R^1 is chloro or methyl.

11. (original) The compound of claim 10, wherein the R^6 phenyl is unsubstituted.

12. (original) The compound of claim 10, wherein the R^6 phenyl is substituted at the 4-position.

13. (original) The compound of claim 12, wherein the R^6 phenyl is substituted with a -(C_1-C_6)alkyl.

14. (original) The compound of claim 13, wherein the -(C_1-C_6)alkyl is a *tert*-butyl group.

15. (original) The compound of claim 13, wherein the -(C_1-C_6)alkyl is an *iso*-propyl group.

16. (original) The compound of claim 12, wherein the R^6 phenyl is substituted with a -CF_3 group.

17. (original) The compound of claim 1, wherein A is -O-.

18. (original) The compound of claim 1, wherein A is -S-.

19. (previously presented) A compound of formula:



(Ia)

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R^2 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})$alkyl, $-(C_2\text{-}C_{10})$alkenyl, $-(C_2\text{-}C_{10})$alkynyl, $-(C_3\text{-}C_{10})$cycloalkyl, $-(C_8\text{-}C_{14})$bicycloalkyl, $-(C_8\text{-}C_{14})$tricycloalkyl, $-(C_5\text{-}C_{10})$cycloalkenyl, $-(C_8\text{-}C_{14})$bicycloalkenyl, $-(C_8\text{-}C_{14})$tricycloalkenyl, $-(C_3\text{-}C_7)$heterocycle, or $-(C_7\text{-}C_{10})$bicycloheterocycle, each of which is unsubstituted or substituted with one or more R^5 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$aryl, or $-(C_5\text{-}C_{10})$heteroaryl, each of which is unsubstituted or substituted with one or more R^7 groups;

each R^3 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$; or

(b) $-(C_1\text{-}C_{10})$alkyl, $-(C_2\text{-}C_{10})$alkenyl, $-(C_2\text{-}C_{10})$alkynyl, $-(C_3\text{-}C_{10})$cycloalkyl, $-(C_8\text{-}C_{14})$bicycloalkyl, $-(C_8\text{-}C_{14})$tricycloalkyl, $-(C_5\text{-}C_{10})$cycloalkenyl, $-(C_8\text{-}C_{14})$bicycloalkenyl, $-(C_8\text{-}C_{14})$tricycloalkenyl, $-(C_3\text{-}C_7)$heterocycle, or $-(C_7\text{-}C_{10})$bicycloheterocycle, each of which is unsubstituted or substituted with one or more R^5 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$aryl or $-(C_5\text{-}C_{10})$heteroaryl, each of which is unsubstituted or substituted with one or more R^7 groups;

each R^5 is independently -CN, -OH, -$(C_1$-$C_6)$alkyl, -$(C_2$-$C_6)$alkenyl, -halo, -N_3, -NO_2, -$N(R^8)_2$, -CH=NR^8, -NR^8OH, -OR^8, -COR^8, -C(O)OR^8, -OC(O)R^8, -OC(O)OR^8, -SR^8, -S(O)R^8, or -$S(O)_2R^8$;

R^6 is:

(a) -naphthyl, -(C_{14})aryl, or -$(C_3$-$C_8)$cycloalkyl each of which is unsubstituted or substituted with one or more R^7 groups; or

(b) pyridyl, furyl, benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, indolyl, oxazolyl, benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiadiazolyl, triazinyl, cinnolinyl, phthalazinyl, or quinazolinyl, each of which is substituted with one or more R^7 groups;

each R^7 is independently -$(C_1$-$C_6)$alkyl, -$(C_2$-$C_6)$alkenyl, -$(C_2$-$C_6)$alkynyl, -$(C_3$-$C_8)$cycloalkyl, -$(C_5$-$C_8)$cycloalkenyl, -phenyl, -$(C_3$-$C_5)$heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -$N(R^8)_2$, -CH=NR^8, -NR^8OH, -OR^8, -COR^8, -C(O)OR^8, -OC(O)R^8, -OC(O)OR^8, -SR^8, -S(O)R^8, or -$S(O)_2R^8$;

each R^8 is independently -H, -$(C_1$-$C_6)$alkyl, -$(C_2$-$C_6)$alkenyl, -$(C_2$-$C_6)$alkynyl, -$(C_3$-$C_8)$cycloalkyl, -$(C_5$-$C_8)$cycloalkenyl, -phenyl, -$(C_3$-$C_5)$heterocycle, -C(halo)$_3$, -CH_2(halo), or -CH(halo)$_2$;

each halo is independently -F, -Cl, -Br or -I;

n is an integer ranging from 0 to 3; and

m is an integer ranging from 0 to 2.

20. (original) The compound of claim 19, wherein R^6 is pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, or thiadiazolyl.

21. (previously presented) A compound of formula:



(Ib)

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is -halo, $-CH_3$, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R^2 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$;

(b) $-(C_1\text{-}C_{10})$alkyl, $-(C_2\text{-}C_{10})$alkenyl, $-(C_2\text{-}C_{10})$alkynyl, $-(C_3\text{-}C_{10})$cycloalkyl, $-(C_8\text{-}C_{14})$bicycloalkyl, $-(C_8\text{-}C_{14})$tricycloalkyl, $-(C_5\text{-}C_{10})$cycloalkenyl, $-(C_8\text{-}C_{14})$bicycloalkenyl, $-(C_8\text{-}C_{14})$tricycloalkenyl, $-(C_3\text{-}C_7)$heterocycle, or $-(C_7\text{-}C_{10})$bicycloheterocycle, each of which is unsubstituted or substituted with one or more R^5 groups; or

(c) -phenyl, -naphthyl, $-(C_{14})$aryl, or $-(C_5\text{-}C_{10})$heteroaryl, each of which is unsubstituted or substituted with one or more R^7 groups;

each R^3 is independently:

(a) -halo, -CN, -OH, $-NO_2$, or $-NH_2$; or

(b) $-(C_1\text{-}C_{10})$alkyl, $-(C_2\text{-}C_{10})$alkenyl, $-(C_2\text{-}C_{10})$alkynyl, $-(C_3\text{-}C_{10})$cycloalkyl, $-(C_8\text{-}C_{14})$bicycloalkyl, $-(C_8\text{-}C_{14})$tricycloalkyl, $-(C_5\text{-}C_{10})$cycloalkenyl, $-(C_8\text{-}C_{14})$bicycloalkenyl, $-(C_8\text{-}C_{14})$tricycloalkenyl, $-(C_3\text{-}C_7)$heterocycle, or $-(C_7\text{-}C_{10})$bicycloheterocycle, each of which is unsubstituted or substituted with one or more R^5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(C_5-C_{10})heteroaryl, each of which is unsubstituted or substituted with one or more R^7 groups;

each R^5 is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -halo, -N_3, -NO_2, -$N(R^8)_2$, -CH=NR^8, -NR^8OH, -OR^8, -COR^8, -C(O)OR^8, -OC(O)R^8, -OC(O)OR^8, -SR^8, -S(O)R^8, or -$S(O)_2R^8$;

each R^7, R^9, and R^{10} is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(C_3-C_5)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -$N(R^8)_2$, -CH=NR^8, -NR^8OH, -OR^8, -COR^8, -C(O)OR^8, -OC(O)R^8, -OC(O)OR^8, -SR^8, -S(O)R^8, or -$S(O)_2R^8$;

each R^8 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(C_3-C_5)heterocycle, -C(halo)$_3$, -CH_2(halo), or -CH(halo)$_2$;

each halo is independently -F, -Cl, -Br or -I;

n is an integer ranging from 0 to 3;

m is an integer ranging from 0 to 2; and

p is an integer ranging from 0 to 4.

22. (previously presented) A compound of formula:



(Ic)

or a pharmaceutically acceptable salt thereof, wherein:

A is -NR^4-, -O-, or -S-;

each R^3 is independently:

(a) -halo, -CN, -OH, -NO_2, or -NH_2; or

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-

C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(C_3-C_7)heterocycle, or -(C_7-C_{10})bicycloheterocycle, each of which is unsubstituted or substituted with one or more R^5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl or -(C_5-C_{10})heteroaryl, each of which is unsubstituted or substituted with one or more R^7 groups;

R^4 is -(C_1-C_6)alkyl, or -O-(C_1-C_6)alkyl;

each R^5 is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -halo, -N_3, -NO_2, -$N(R^8)_2$, -CH=NR^8, -NR^8OH, -OR^8, -COR^8, -C(O)OR^8, -OC(O)R^8, -OC(O)OR^8, -SR^8, -S(O)R^8, or -$S(O)_2R^8$;

R^6 is -phenyl, -naphthyl, -(C_3-C_8)cycloalkyl, -(C_{14})aryl, or -(C_5-C_{10})heteroaryl, each of which is unsubstituted or substituted with one or more R^7 groups;

each R^7 is independently -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(C_3-C_5)heterocycle, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -CN, -OH, -halo, -N_3, -NO_2, -$N(R^8)_2$, -CH=NR^8, -NR^8OH, -OR^8, -COR^8, -C(O)OR^8, -OC(O)R^8, -OC(O)OR^8, -SR^8, -S(O)R^8, or -$S(O)_2R^8$;

each R^8 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(C_3-C_5)heterocycle, -C(halo)$_3$, -CH_2(halo), or -CH(halo)$_2$;

R^{11} is -hydrogen, -halo, -CH_3, -NO_2, -CN, -OH, -OCH_3, -NH_2, -C(halo)$_3$, -CH(halo)$_2$, or -CH_2(halo);

each R^{12} is independently:

(a) -halo, -CN, -OH, -NO_2, or -NH_2;

(b) -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, -(C_3-C_{10})cycloalkyl, -(C_8-C_{14})bicycloalkyl, -(C_8-C_{14})tricycloalkyl, -(C_5-C_{10})cycloalkenyl, -(C_8-C_{14})bicycloalkenyl, -(C_8-C_{14})tricycloalkenyl, -(C_3-C_7)heterocycle, or -(C_7-C_{10})bicycloheterocycle, each of which is unsubstituted or substituted with one or more R^5 groups; or

(c) -phenyl, -naphthyl, -(C_{14})aryl, or -(C_5-C_{10})heteroaryl, each of which is unsubstituted or substituted with one or more R^7 groups;

m is an integer ranging from 0 to 2; and

q is an integer ranging from 0 to 3.

23.-101. (canceled)

102. (original) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

103. (original) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 19 and a pharmaceutically acceptable carrier or excipient.

104. (original) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21 and a pharmaceutically acceptable carrier or excipient.

105. (original) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 22 and a pharmaceutically acceptable carrier or excipient.

106.-116. (canceled)

117. (original) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

118. (original) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 19.

119. (original) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

120. (original) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 22.

121.-191. (canceled)

192. (original) A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

193. (original) A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 19.

194. (original) A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

195. (original) A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 22.

196.-221. (canceled)

222. (original) A method for preparing a composition, the method comprising admixing a compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

223. (original) A method for preparing a composition, the method comprising admixing a compound or a pharmaceutically acceptable salt of the compound of claim 19 and a pharmaceutically acceptable carrier or excipient.

224. (original) A method for preparing a composition, the method comprising admixing a compound or a pharmaceutically acceptable salt of the compound of claim 21 and a pharmaceutically acceptable carrier or excipient.

225. (original) A method for preparing a composition, the method comprising admixing a compound or a pharmaceutically acceptable salt of the compound of claim 22 and a pharmaceutically acceptable carrier or excipient.

226.-237. (canceled)

238. (previously presented) The compound of claim 21, wherein:
n is 0; and

m is 0.

239. (previously presented) The compound of claim 238, wherein p is 0.

240. (previously presented) The compound of claim 239, wherein R^9 is a -(C_1-C_6)alkyl.

241. (previously presented) The compound of claim 240, wherein the -(C_1-C_6)alkyl is a *tert*-butyl group.

242. (previously presented) The compound of claim 240, wherein the -(C_1-C_6)alkyl is an *iso*-propyl group.

243. (previously presented) The compound of claim 239, wherein R^9 is a -C(halo)$_3$ group.

244. (previously presented) The compound of claim 243, wherein the -C(halo)$_3$ group is a CF_3 group.

245. (previously presented) The compound of claim 239, wherein R^9 is an -OC(halo)$_3$ group.

246. (previously presented) The compound of claim 245, wherein the -OC(halo)$_3$ group is an OCF_3 group.

247. (previously presented) The compound of claim 239, wherein R^1 is chloro or methyl.

248. (previously presented) The compound of claim 247, wherein R^9 is a -(C_1-C_6)alkyl.

249. (previously presented) The compound of claim 248, wherein the -(C_1-C_6)alkyl is a *tert*-butyl group.

250. (previously presented) The compound of claim 248, wherein the -(C_1-C_6)alkyl is an *iso*-propyl group.

251. (previously presented) The compound of claim 247, wherein R^9 is a -C(halo)$_3$ group.

252. (previously presented) The compound of claim 251, wherein the -C(halo)$_3$ group is a CF_3 group.

253. (previously presented) The compound of claim 247, wherein R^9 is an -OC(halo)$_3$ group.

254. (previously presented) The compound of claim 253, wherein the -OC(halo)$_3$ group is an OCF_3 group.

255. (previously presented) The compound of claim 21, wherein:
n is 0; and
m is 1.

256. (previously presented) The compound of claim 255, wherein R^3 is a -(C_1-C_{10})alkyl and p is 0.

257. (previously presented) The compound of claim 256, wherein the -(C_1-C_{10})alkyl is a methyl group.

258. (previously presented) The compound of claim 256, wherein R^9 is a -(C_1-C_6)alkyl.

259. (previously presented) The compound of claim 258, wherein the -(C_1-C_6)alkyl is a *tert*-butyl group.

260. (previously presented) The compound of claim 258, wherein the -(C_1-C_6)alkyl is an *iso*-propyl group.

261. (previously presented) The compound of claim 256, wherein R^9 is a -C(halo)$_3$ group.

262. (previously presented) The compound of claim 261, wherein the -C(halo)$_3$ group is a CF_3 group.

263. (previously presented) The compound of claim 256, wherein R^9 is an -OC(halo)$_3$ group.

264. (previously presented) The compound of claim 263, wherein the -OC(halo)$_3$ group is an OCF_3 group.

265. (previously presented) The compound of claim 256, wherein R^1 is chloro or methyl.

266. (previously presented) The compound of claim 265, wherein R^9 is a -(C_1-C_6)alkyl.

267. (previously presented) The compound of claim 266, wherein the -(C_1-C_6)alkyl is a *tert*-butyl group.

268. (previously presented) The compound of claim 266, wherein the -(C_1-C_6)alkyl is an *iso*-propyl group.

269. (previously presented) The compound of claim 265, wherein R^9 is a -C(halo)$_3$ group.

270. (previously presented) The compound of claim 269, wherein the -C(halo)$_3$ group is a CF_3 group.

271. (previously presented) The compound of claim 265, wherein R^9 is an -OC(halo)$_3$ group.

272. (previously presented) The compound of claim 271, wherein the -OC(halo)$_3$ group is an OCF_3 group.

273. (previously presented) The compound of claim 262, wherein R^1 is chloro and R^3 is a methyl group.